DOI: 10.14704/nq.2017.15.3.1074

A Brief History of Steroid Therapy for Guillain-Barré Syndrome

Xing Ning, Yin Liyong, Lan Xifa


Steroids have been used for the treatment of Guillain-Barré Syndrome (GBS) since the 1950s, while their clinical efficacy remains poorly defined. Most randomized controlled trials after the 1970s yielded no clues for significant differences between steroid therapy and symptomatic supportive therapy, while after adjusting the factors that affected the biases, the reanalysis of the two trials with the largest number of samples among them showed that intravenous methylprednisolone was superior to symptomatic supportive therapy, or its combination with intravenous immunoglobulin exhibited superior effects. To date, there is still no strong evidence proving or denying the efficacy of high-dose methylprednisolone, and further studies are still merited for issues regarding steroids for GBS.


GBS; steroid; plasma exchange; immunoglobulin

Full Text:



Asbury AK. Guillain-Barré syndrome: historical aspects. Annals of Neurology 1990; 27 (Suppl): S2-6.

Blood A, locke W, carabasi R. Guillain-Barré syndrome treated with corticotropin (ACTH). Journal of the American Medical Association 1953; 152 (2): 139-40.

Chhuttani PN, Chawla LS, Chugh KS, Singh H. Landry-Guillain-Barré-Strohl syndrome in India. Journal of the Neurological Sciences 1968; 7 (3): 581-92.

Fazlullah S. Landry-Guillain-Barré syndrome treatment with ACTH and Cortisone. Postgraduate Medical Journal 1956; 32 (365): 150-54.

Goodall JA, Kosmidis JC, Geddes AM. Effect of corticosteroids on course of Guillain-Barré syndrome. The Lancet 1974; 1 (7857): 524-26.

Graveson GS. The use of steroids in the treatment of the Guillain-Barre syndrome. Proceedings of the Royal Society of Medicine 1961; 54 (7): 575-76.

Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. The Lancet 1993; 341 (8845): 586–90.

Haass A, Trabert W, Gressnich N, Schimrigk K. High-dose steroid therapy in Guillain-Barré syndrome. Journal of Neuroimmunology 1988; 20 (2): 305-08.

Haymaker WE, Kernohan JW. The Landry-Guillain-Barré syndrome; a clinicopathologic report of 50 fatal cases and a critique of the literature. Medicine 1949; 28 (1): 59-141.

Heller GL, Dejong RN. Treatment of the Guillain-barre syndrome: use of corticotropin and glucocorticoids. Archives of Neurology 1963; 8 (2): 179-93.

Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2016; (10): CD001446.

Hughes RA, Swan AV, van Koningsveld R, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2006; (2): CD001446.

Hughes RA, van der Meché FG. Corticosteroids for treating Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2000; (2): CD001446.

Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003; 61 (6): 736-40.

Hughes RAC, Kadlubowski M, Hufschmidt A. Treatment of acute inflammatory polyneuropathy. Annals of Neurology 1981; 9 (Suppl): 125–33.

Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. The Lancet 1978; 2 (8093): 750–3.

Hughes RAC, Swan AV, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2010; (2): CD001446.

Jackson RH, Miller H, Schapira K. Polyradiculitis (Landry-Guillain-Barré syndrome) treatment with cortisone and corticotrophin. British Medical Journal 1957; 1: 480-4.

King RH, Craggs RI, Gross ML, Thomas PK. Effects of glucocorticoids on experimental allergic neuritis. Experimental Neurology 1985; 87 (1): 9-19.

Levchenko NI, Piradov MA, Pirogov VN. Plasmapheresis and hormone therapy in severe forms of Guillain-Barré syndrome. Klinicheskaia Meditsina 1989; 67 (12): 88–91.

Löffel NB, Rossi LN, Mumenthaler M, Lütschg J, Ludin HP. The Landry-Guillain-barré syndrome. Complications, prognosis and natural history in 123 cases. Journal of The Neurological Sciences. 1977; 33: 71-9.

Marshall J. The Landry-Guillain-Barré Syndrome. Brain 1963; 86 (1): 55-66.

McFarland HR. The Guilalin-Barre Disease Complex. An Analysis of the Disease with Therapeutic Suggestions and Report of 26 Cases. California Medicine 1960; 93 (3): 141-47.

Moore P, James O. Guillain-Barré Syndrome: incidence, management and outcome of major complications. Critical Care Medicine 1981; 9 (7): 549-55.

Pollard JD. A critical review of therapies in acute and chronic inflammatory demyelinating polyneuropathies. Muscle & Nerve 1987; 10 (3): 214-21.

Shy GM, McEachern D. Further studies of the effects of cortisone and ACTH on neurological disorders. Brain 1951; 74 (3): 354-62.

Steiner I, Wirguin I, Abramsky O. Appearance of Guillain-Barré syndrome in patients during corticosteroid treatment. Journal of Neurology 1986; 233 (4): 221-23.

Swick HM, McQuillen MP. The use of steroids in the treatment of idiopathic polyneuritis. Neurology 1976; 26 (3): 205-12.

The Dutch Guillain-Barré Study Group. Treatment of Guillain- Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Annals of Neurology 1994; 35 (6): 749–52.

Van Koningsveld R, Schmitz PIM, Van der Meché FGA, Visser VH, Meulstee J, Van Doorn PA. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. The Lancet 2004; 363 (9404): 192–96.

Van Koningsveld R, Van Doorn PA. Steroids in the Guillain-Barré syndrome: is there a therapeutic window? Neurologia 2005; 20 (2): 53-57.

Vernon MA. Guillain-Barre syndrome treated with ACTH and cortisone. Canadian Medical Association Journal 1954; 70 (1): 75-76.

Watts PM, Taylor WA, Hughes RA. High-dose methylprednisolone suppresses experimental allergic neuritis in the Lewis rat. Experimental Neurology 1989; 103 (1): 101-04.

Supporting Agencies

| NeuroScience + QuantumPhysics> NeuroQuantology :: Copyright 2001-2019